Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.

@article{Lacy2009IdiotypepulsedAC,
  title={Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.},
  author={Martha Q. Lacy and Sumithra J. Mandrekar and Angela Dispenzieri and Suzanne R. Hayman and Shaji K Kumar and Francis K Buadi and David Dingli and Mark R Litzow and Peter J. Wettstein and Douglas J Padley and Brian F. Kabat and Dennis A Gastineau and S Vincent Rajkumar and Morie A Gertz},
  journal={American journal of hematology},
  year={2009},
  volume={84 12},
  pages={799-802}
}
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty-seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124… CONTINUE READING